Cargando…

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

INTRODUCTION: Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease reactivation. Currently no disease-modifying drug (DMD) has been shown to be able to abolish disease reactivation. The aims of the current study were: (1) to determine the frequency of MS reactivation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lo Re, Marianna, Capobianco, Marco, Ragonese, Paolo, Realmuto, Sabrina, Malucchi, Simona, Berchialla, Paola, Salemi, Giuseppe, Bertolotto, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685862/ https://www.ncbi.nlm.nih.gov/pubmed/26647006 http://dx.doi.org/10.1007/s40120-015-0038-9

Ejemplares similares

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study
por: Ragonese, Paolo, et al.
Publicado: (2017)

Klotho and vitamin D in multiple sclerosis: an Italian study
por: Scazzone, Concetta, et al.
Publicado: (2019)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population
por: Conway, Devon S, et al.
Publicado: (2020)

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2022)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid
por: Geraci, Fabiana, et al.
Publicado: (2018)

Four cases of progressive multifocal leukoencephalopathy in iatrogenic immunocompromised patients
por: Bianchi, Alessia, et al.
Publicado: (2020)

The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy
por: Giacoppo, Sabrina, et al.
Publicado: (2017)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Natalizumab treatment reduces microglial activation in the white matter of the MS brain
por: Sucksdorff, Marcus, et al.
Publicado: (2019)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Fatal COVID-19 in an MS patient on natalizumab: A case report
por: Rimmer, Kathryn, et al.
Publicado: (2020)

Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS
por: Hersh, Carrie M, et al.
Publicado: (2021)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Comparison of the Intestinal Microbiome of Italian Patients with Multiple Sclerosis and Their Household Relatives
por: Galluzzo, Paola, et al.
Publicado: (2021)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
por: Diotti, Roberta Antonia, et al.
Publicado: (2016)

Natalizumab alters the TCR repertoire after one year of treatment in four MS patients
por: Michel, Laure, et al.
Publicado: (2011)

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles
por: de la Hera, Belén, et al.
Publicado: (2014)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis
por: Gilli, Francesca, et al.
Publicado: (2010)

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
por: Evdoshenko, Evgeniy, et al.
Publicado: (2019)

Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
por: Masuccio, Fabio Giuseppe, et al.
Publicado: (2020)

Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual Subjects
por: Troni, Walter, et al.
Publicado: (2016)

Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α Therapy
por: Motuzova, Yana, et al.
Publicado: (2015)

Lymphocyte recovery after fingolimod discontinuation in patients with MS
por: Nagy, Sara, et al.
Publicado: (2020)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_c6oe9dibper3qg9ptmo5qsu9l7